Trials / Conditions / HIV Wasting Syndrome

HIV Wasting Syndrome

12 registered clinical trials studyying HIV Wasting Syndrome.

Status	Trial	Sponsor	Phase
Completed	Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weig NCT00637572	Endo Pharmaceuticals	Phase 2
Completed	The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children NCT00006064	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	A Study to Evaluate High Protein Supplementation in HIV-Positive Patients With Stable Weight Loss NCT00000925	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Nutrition Intervention in AIDS Wasting NCT00006167	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4
Completed	Growth Hormone in the Treatment of HIV-Associated Wasting NCT00489528	EMD Serono	Phase 3
Completed	A Comparison of Two Caloric Supplements in the Prevention of Weight Loss in Patients With AIDS Who Take Daily NCT00001077	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV NCT00004664	National Center for Research Resources (NCRR)	N/A
Completed	A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss NCT00000854	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for NCT00000737	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1
Completed	A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in NCT00002127	Celgene Corporation	Phase 2
Completed	A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV- NCT00001079	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome NCT00002157	Celgene Corporation	N/A